Lifeward Ltd., a leader in innovative medical technology, announced the successful closing of its public offering, raising approximately $2.6 million. The offering included 4,000,000 ordinary shares and accompanying warrants to purchase an equal number of shares at $0.65 each. The warrants are immediately exercisable and expire in five years. H.C. Wainwright & Co. served as the exclusive placement agent. The proceeds will support Lifeward's commercial efforts, working capital, and general corporate purposes.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。